XPO1 Inhibitors
1 drugsAbout XPO1
XPO1 (exportin 1) mediates the transport of proteins and RNA out of the cell nucleus, a process essential for cellular function. By regulating the location of key proteins, XPO1 plays a critical role in maintaining cellular homeostasis.
XPO1 is a compelling oncology target because tumor suppressor proteins are often exported from the nucleus in cancer cells. Inhibiting XPO1 retains these proteins in the nucleus, potentially restoring their tumor-suppressing activity. There is currently no genetic evidence directly linking XPO1 to specific diseases.
XPO1 is targeted by one FDA-approved drug, XPOVIO, a small molecule developed by Karyopharm Therapeutics. XPOVIO was first approved in 2019 for oncology indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Malignant Glioma with only 2 trials.
- phase2 represents biological uncertainty with 43% completion.
Top XPO1 Drugs
Karyopharm Therapeutics is the only company with an approved drug targeting XPO1.
High market concentration suggests high entry barriers or limited interest from other companies.
XPO1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets XPO1, using small molecule modality.
The exclusive use of small molecules indicates a whitespace opportunity for alternative modalities like antibodies or PROTACs.
XPO1 Clinical Trials 152 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 64 | 28 | 15 | 21 | 65% |
| Phase 2 | 74 | 11 | 18 | 43 | 38% |
| Phase 3 | 14 | 3 | 1 | 10 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
4 Phase 3 trials testing approved XPO1 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting XPO1. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
XPO1 Drug Approval Timeline (2019 - 2019)
XPOVIO was the first and only drug approved for XPO1 in 2019.
The single approval suggests potential for further drug development or market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 134 clinical trials targeting XPO1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities